Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generates chimeric antigen receptor (CAR) T cells directly in vivo to bypass the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required […]